
Government industrial policy, such as the CHIPS Act, is creating powerful investment tailwinds for the domestic semiconductor and EV battery supply chains. This reshoring trend is validated by major companies like TSMC (TSM) shifting capital investment into the United States. A similar opportunity may be emerging in the pharmaceutical sector, where potential tariffs could benefit US-based drug manufacturers and Contract Development and Manufacturing Organizations (CDMOs). For the broader manufacturing recovery, investors should monitor real factory construction spending as a key leading indicator. These policies are creating a multi-year opportunity in companies central to rebuilding America's industrial base.

By Andreessen Horowitz
The a16z Podcast discusses tech and culture trends, news, and the future – especially as ‘software eats the world’. It features industry experts, business leaders, and other interesting thinkers and voices from around the world. This podcast is produced by Andreessen Horowitz (aka “a16z”), a Silicon Valley-based venture capital firm. Multiple episodes are released every week; visit a16z.com for more details and to sign up for our newsletters and other content as well!